Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes

Type 1 diabetes is characterized by a loss of tolerance to pancreatic beta-cell autoantigens and defects in regulatory T-cell (Treg) function. In preclinical models, immunotherapy with MHC-selective, autoantigenic peptides restores immune tolerance, prevents diabetes, and shows greater potency when multiple peptides are used. To translate this strategy into the clinical setting, we administered a mixture of six HLA-DRB1*0401-selective, beta-cell peptides intradermally to patients with recent-onset type 1 diabetes possessing this genotype in a randomized placebo-controlled study at monthly doses of 10, 100, and 500 mu g for 24 weeks. Stimulated C-peptide (measuring insulin functional reserve) had declined in all placebo subjects at 24 weeks but was maintained at >= 100% baseline levels in one-half of the treated group. Treatment was accompanied by significant changes in islet-specific immune responses and a dose-dependent increase in Treg expression of the canonical transcription factor FOXP3 and changes in Treg gene expression. In this first-in-human study, multiple-peptide immunotherapy shows promise as a strategy to correct immune regulatory defects fundamental to the pathobiology of autoimmune diabetes.

Automated summary

Type 1 diabetes is caused by a loss of tolerance to pancreatic beta-cell autoantigens and defects in regulatory T-cell function. Immunotherapy with multiple peptides has shown promise in preclinical models and a clinical study demonstrated that it can restore immune tolerance and maintain C-peptide levels in newly diagnosed type 1 diabetes patients. This therapy also resulted in changes in immune responses and regulatory T-cell gene expression.